Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Holtzman
Washington University, Department: Neurology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Denali Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Based on Washington University’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, Washington University determined Dr. Holtzman’s personal financial relationship with Denali, related to the above referenced research, creates a financial conflict of interest due to the following reasons:
• Dr. Holtzman’s personal financial relationship is directly related to the research because the research is evaluating a technology developed by Dr. Holtzman which is licensed to Denali.
• The research could directly benefit Denali
• Dr. Holtzman’s role as described below could directly affect the research
While the committees determined financial conflicts of interest exist, they concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research, based on the following reasons:
• The research is basic in nature and in its early stages
• The research is unlikely to have an immediate and direct effect on the value of the entity
• The PI of the study, Dr. Monica Xiong, has no financial interest with Denali
• Additionally, a plan has been developed to mitigate the financial conflict of interest.
The efficacy of human apolipoprotein E4 immunotherapy on cerebral amyloid angiopathy and vascular dysfunction in 5XFAD/apoE4 mice
PROJECT NARRATIVE As advancements in technology and medicine continue to increase the average life span of people worldwide, the prevalence of age-related neurodegenerative diseases is escalating at an alarming rate. According to the World Alzheimer Report, an estimated number of 5.7 million people in the United States alone currently have Alzheimer?s disease (AD), and without a treatment this number is projected to triple by 2050. Thus, the objective of our research is to understand the underlying mechanisms of a novel monoclonal antibody targeting apolipoprotein E in amyloid-? plaques, and its ability to ameliorate plaque pathology in the vasculature and to restore blood vessel function that is often compromised in AD.
Filed on November 01, 2018.
Tell us what you know about David Holtzman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Holtzman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly | $0 - $4,999 |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Therapeutics | $20,000 - $39,999 |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | C2N Diagnostics | $20,000 - $39,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Denali Therapeutics | Value cannot be readily determined |
| David Holtzman | Washington University | Conflict of Interest | Eli Lilly and Company | $0 - $4,999 |
| David Holtzman | Ut Southwestern Medical Center | Conflict of Interest | C2N Diagnostics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.